Intel shares post worst one-day drop since 1974 after earnings
Intel stock fell 29% Friday as weak PC sales and a disappointing fourth-quarter outlook overshadowed a strong beat in AI data-center revenue.
Intel shares collapsed 29% on Friday to close around $65, their worst single-day performance since 1974, after the chipmaker's third-quarter report paired a data-center beat with a disappointing outlook for the current quarter. The stock had been up roughly 150% for the year heading into the report, according to CNBC.
Intel beat earnings-per-share estimates but revenue came in slightly below consensus. Data center and AI revenue rose nearly 80% year over year to $7.3 billion, topping expectations, and CEO Lip-Bu Tan said he expects industrywide server CPU unit growth of 30% in both 2026 and 2027. Management pointed to an explosion at an Israeli fab earlier in the month as a factor slowing data-center output.
Guidance spooks Wall Street
Intel's PC business was weak, which executives blamed partly on elevated memory-chip prices, and the company warned the PC slump would extend into next year. Fourth-quarter guidance also missed the mark: Intel projected adjusted earnings of 25 cents per share on revenue of $15 billion to $16 billion, versus consensus of 43 cents per share and $17.1 billion, according to a separate CNBC markets report. Bank of America, Roth Capital Partners and Seaport Research Partners all cut Intel to neutral from buy; New Street Research upgraded the stock to buy from neutral.
The drop also hit an unusual shareholder: the U.S. government, which holds roughly 433 million Intel shares after taking an equity stake in the company earlier this year. CNBC calculated that stake lost about $11 billion in value on Friday alone, though the position remains up roughly $20 billion overall given the government's $20.47 average purchase price.

Marvell shares tumble as Lumentum soars on report of advanced buyout talks

NatWest profit beats forecasts but shares post worst drop since March on 2027 margin guidance

AbbVie raises profit outlook as Skyrizi and Rinvoq offset Humira's decline
